Cefazolin Recalled

On July 24, 2026, Baxter International Inc. initiated a voluntary recall of cefazolin in dextrose injection, USP, 2g/100mL (20mg/mL), single-dose infusion bag, 100mL. The recall was prompted by particulate matter identified as cardboard found in the solution, which has a reasonable probability of causing pulmonary emboli and occlusion of other blood vessels, potentially leading to tissue death, organ damage or phlebitis. Additionally, infused foreign particles can trigger immune system activation, organ dysfunction and hemolysis. Cefazolin is FDA-approved for the treatment of susceptible bacterial infections and for prevention of infection before surgery. For more information, see here.